MEMPHASYS LIMITED. — Major Shareholding Notification 2011

Mar 17, 2011

FOR IMMEDIATE RELEASE

Significant Shareholder Notice

SYDNEY, AUSTRALIA – 18 March 2011: NuSep Limited (ASX: NSP), attached notices have been received by the Company.

**ENDS**

For more information please contact:

Contact: Prakash Patel Company Secretary +61 2 8415 7300 prakash.patel@nusep.com

Released through: Fergus Ross, Six Degrees Investor Communication: +61 420 980 448

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from Fraction to Function. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

• Gels NuSep manufactures and sells precast gels including the innovative ɳUView Gels, which can be visualised 2 minutes after use.
• Separation Instruments NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF and is expected to undergoing clinical trials later this year.
• Proteomics Software NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.
• Biological Products NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website www.NuSep.com

NuSep Holdings Ltd 324 Burns Bay Rd Lane Cove NSW 2066 Postal Address P.O. Box 823 Lane Cove NSW 1595 Contact Details Telephone +61 2 8415 7300 Facsimile +61 2 8415 7399

Email info@nusep.com Web www.nusep.com ABN 33 120 047 556

About SingaPharm

SingaPharm is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. SingaPharm is currently a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). SingaPharm's process is based on the Preparative Isolation by Membrane Electrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is 'electronically' driven membrane fractionation.

This process is flexible and modular compared with the large scale inflexible processing facilities of existing fractionators in US and Europe. The process has increased product yield relative to the existing process with increased product safety. The flexible nature of the PrIME technology also provides SingaPharm with access to plasma volumes that previously did not meet the criteria for larger scale processing facilities. Further, SingaPharm's process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

		604	page 1/2 15 July 2001
	Form 604
	Corporations Ant 2001 Section 671B
	Notice of change of interests of substantial holder
In Company Name/Scheme	WOSEP HOWEVES CTD
ACN/ARSN	$22 -$ 120 047 556
1. Details of substantial holder(1)
Name ACN/ARSN (if applicable)	Archew Empot Good-11
There was a change in the interests of the substantiel holder on
The previous notice was given to the company on The previous notice was dated	1.5/300 161,0010
2. Previous and present voting power

The total number of votes ettoched to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3)
in when hest required, and when now r

Class of securities (4)	Previous notice	Present rodice
	Parson's votes Voting power (5)	Person's voues Voting cower (5
CHEINELL ****	$21 - 65$

3. Changes in relevant interests

Particulars of each change in, or change in the return of, a relevant interest of the substantial noter or an associate in voting securities of the company or scheme, since the
substantial holder was last required to give

changed	change (6)	given in relation to charige (7)	number of SACUTIONS affected	affected
$-5$	Market	$252.083 - 91145832$

4. Present celevam interests

Particulars of each relevant Interest of the substantial holder in voting securities after the change ere es follows:

Holder of ralevant interest	Registered holder of securities	Person enritled to be registarad as holder (B)	Nature of nelevant interest (B)	Class and number of SECUTICIES	Person's votes
	rekch-al		SIREC-
				$-41.5$

Pase: 2/3

ASPER IMPORTS

$\int_0^{\infty}$

		604
			page 2/2 15 July 2001
		5. Changes In association The persons who have become associates (2) of, caused to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or schame are as follows:
		Name and ACN/ARSN (if applicable) Neture of association
	5. Addresses
		The addresses of persons named in this form are es follows:
		Name Address GOODALL 554
		Marvilleunback NSW 2484
	Signature
		print name Goodah capacity
		al foodall zign hera date $1810312011$
		DIRECTIONS
(1)
		If there are a number of substantial holders with similar or relevent elevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names cauld be included in an ennexure to the form. If the relevant interests of a group of persons are essent ally similar, they may be referred to throughout the form as a specifically ratried group if the membership of each group, with the names and addresses of members is clearly set out in perigraph 6 of the
囟		See the definition of "associate" in section 9 of the Corporations Act 2001.
$\left(3\right)$		See the definition of Televant interest" in sections 608 and 6718(7) of the Corporations Act 2001.
$\langle 4 \rangle$		The voting shares of a company constitute one class unless divided into separate classes.
(Š)		The person's votas divided by the total votes in the body corporate or scheme multiplied by 100.
(6)	间)	Include details of: any ratevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 6718(4) applies, a copy of any
	Đ)	document setting out the terms of any relevant egreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must, accompany this form, together with a written statement cartifying this contract, scheme or arrangement; and
		any qualification of the power of a person to exercise, commol the exercise of, or influence the exercise of, the voting powers or disposer of the securities to which the relevant interest ralates (indicating clearly the perticular securities to which the qualification applies). See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
(7)		Details of the consideration must include any and all benefits, money and other, that any person from whem a relevant interest was anquired has or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be
$^{(8)}$		included of any benefit paid on behalf of the autostantial holder or its associate in relation to the acculations, aven if they are not peid directly to the person from whom the relevant interest was acquired.
(9)		If the substantiel holder is unable to determine the identity of the person (eg. If the relevent intentet arises because of an option) write "unknown".
		Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

Form 605

Corporations Act 2001 Section 671B

Notice of ceasing to be a substantial holder

To Company Name/Scheme
ACN/ARSN

1. Details of substantial holder(1)

	To Company Name/Scheme
ACN/ARSN
	1. Details of substantial holder(1)
Name
ACN/ARSN (if applicable)
The holder ceased to be a substantial holder on	The previous notice was given to the company on The previous notice was dated		/ / / / / /
	2. Changes in relevant interests
		Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:
	Date of change	Person whose relevant interest changed	Nature of change (4)		Consideration given in relation to change(5)	Class (6) and number of securities affected	Person's votes affected
	3. Changes in association interests in the company or scheme are as follows:	The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting
		Name and ACN/ARSN (if applicable)		Nature of association
4. Addresses
		The addresses of persons named in this form are as follows:
	Name			Address
Signature
	print name				capacity
	sign here				date	/ /

2. Changes in relevant interests

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change(5)	Class (6) and number of securities affected	Person's votes affected

3. Changes in association

Name and ACN/ARSN (if applicable)	Nature of association

4. Addresses

Name	Address

Signature

print name	capacity
sign here	date / /

Annex 1
3. Changes in relevant interests
Date of	Person whose	Nature of	Consideration	Class (6) and	Person's votes
Change	relevant interest	change (4)	given in	number of	affected
	changed		relation	securities
			to change (5)	affected
20 Aug 2010	Andrew Winston Doyle	Market Sale	\$4,095.05	15,000	15,000
26 Aug 2010	Andrew Winston Doyle	Market Purchase	\$3,704.95	15,000	15,000
21 Oct 2010	Andrew Winston Doyle	Market Purchase	\$6,779.95	25,000	25,000
22 Oct 2010	Andrew Winston Doyle	Market Purchase	\$6,750.00	25,000	25,000
25 Oct 2010	Andrew Winston Doyle	Market Purchase	\$905.78	3,305	3,305
27 Oct 2010	Andrew Winston Doyle	Market Purchase	\$9,051.94	30,000	30,000
29 Nov 2010	Andrew Winston Doyle	Market Sale	\$2,781.86	10,000	10,000
14 Dec 2010	Andrew Winston Doyle	Issue	\$168,000.00	800,000	800,000
02 Mar 2011	Andrew Winston Doyle	Market Sale	\$12,372.47	61,750	61,750
16 Mar 2011	Andrew Winston Doyle	Market Sale	\$8,050.00	40,250	40,250